ERBB2 and breast cancer: This retrospective study reviewed the clinical records of 94 female patients with HER2-positive breast cancer who received combined subcutaneous injections of pertuzumab and trastuzumab at the Affiliated Hospital of Southwest Medical University (Luzhou, China) between January 2024 and March 2025.